[ Price : $8.95]
A Phase 3 trial funded by Novo Nordisk showed that its Ozempic/Wegovy outperformed placebo in patients with steatohepatitis and fi...[ Price : $8.95]
Chemistry & Engineering News reports that reductions in CDER Division of Drug Information staff are affecting FDAs ability to main...[ Price : $8.95]
A self-described radical HHS policy now requires all new vaccines to be evaluated in placebo-controlled trials before theyre licen...[ Price : $8.95]
FDA extends by three months its review of a Cytokinetics NDA for aficamten for treating patients with obstructive hypertrophic car...[ Price : $8.95]
FDA approves a Satsuma Pharmaceuticals 505(b)(2) NDA for Atzumi (dihydroergotamine (DHE)) nasal powder for the acute treatment of ...[ Price : $8.95]
FDA approves a Johnson & Johnson BLA for Imaavy (nipocalimab-aahu) for treating generalized myasthenia gravis.[ Price : $8.95]
George Washington University law professor Richard Pierce praises a recent unanimous Supreme Court decision backing FDA in an e-ci...[ Price : $8.95]
Boehringer Ingelheim releases new findings from its Beamion LUNG-1 trial, highlighting the potential of zongertinib as a breakthro...